# Annex 1: Recommended Indicators

## PROPOSED GOAL-LEVEL INDICATORS & TARGETS

<table>
<thead>
<tr>
<th>GOAL</th>
<th>TARGET BY 2015</th>
<th>TARGET BY 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achieve a world free of poliomyelitis</td>
<td>Interrupt wild poliovirus transmission globally (by 2014)</td>
<td>Certification of poliomyelitis eradication (by 2018)</td>
</tr>
<tr>
<td>Meet global and regional elimination targets</td>
<td>Neonatal tetanus eliminated in all WHO regions</td>
<td>Measles and rubella eliminated in at least five WHO regions</td>
</tr>
<tr>
<td></td>
<td>Measles eliminated in at least four WHO regions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rubella/congenital rubella syndrome eliminated in at least two WHO regions</td>
<td></td>
</tr>
<tr>
<td>Meet vaccination coverage targets in every region, country and community</td>
<td>Reach 90% national coverage and 80% in every district or equivalent administrative unit with three doses of diphtheria-tetanus-pertussis-containing vaccines</td>
<td>Reach 90% national coverage and 80% in every district or equivalent administrative unit with all vaccines in national programmes, unless otherwise recommended</td>
</tr>
<tr>
<td>Develop and introduce new and improved vaccines and technologies</td>
<td>At least 90 low-income and middle-income countries have introduced one or more new or underutilized vaccines</td>
<td>All low-income and middle-income countries have introduced one or more new or underutilized vaccines</td>
</tr>
<tr>
<td></td>
<td>Licensure and launch of vaccine or vaccines against one or more major currently non-vaccine preventable diseases</td>
<td>Licensure and launch of at least one platform delivery technology</td>
</tr>
<tr>
<td>Exceed the Millennium Development Goal 4 target for reducing child mortality</td>
<td>Reduce by two thirds, between 1990 and 2015, the under-five mortality rate (Target 4A)</td>
<td>Exceed the Millennium Development Goal 4 Target 4A for reducing child mortality</td>
</tr>
</tbody>
</table>

1 These proposed indicators will be presented to the WHO EB and World Health Assembly for final review in 2013. The Strategic Advisory Group of Experts on immunization will also consider the development and addition of indicators to monitor equity in access to vaccines between countries, and integration of immunization systems into broader health systems, respectively.
PROPOSED STRATEGIC OBJECTIVE-LEVEL INDICATORS

1. **ALL COUNTRIES COMMIT TO IMMUNIZATION AS A PRIORITY.**
   - Domestic expenditures for immunization per person targeted
   - Presence of an independent technical advisory group that meets defined criteria

2. **INDIVIDUALS AND COMMUNITIES UNDERSTAND THE VALUE OF VACCINES AND DEMAND IMMUNIZATION BOTH AS A RIGHT AND A RESPONSIBILITY.**
   - Percentage of countries that have assessed (or measured) confidence in vaccination at subnational level
   - Percentage of un- and under-vaccinated in whom lack of confidence was a factor that influenced their decision

3. **THE BENEFITS OF IMMUNIZATION ARE EQUITABLY EXTENDED TO ALL PEOPLE.**
   - Percentage of districts with 80% or greater coverage with three doses of diphtheria-tetanus-pertussis-containing vaccine
   - Reduction in coverage gaps between lowest and highest wealth quintile and another appropriate equity indicator

4. **STRONG IMMUNIZATION SYSTEMS ARE AN INTEGRAL PART OF A WELL-FUNCTIONING HEALTH SYSTEM.**
   - Dropout rate between first dose and third dose of diphtheria-tetanus-pertussis-containing vaccines
   - Sustained coverage of diphtheria-tetanus-pertussis-containing vaccines ≥90% for three or more years
   - Immunization coverage data assessed as high quality by WHO and UNICEF
   - Number of countries with case-based surveillance for vaccine-preventable diseases that meet quality standards

5. **IMMUNIZATION PROGRAMMES HAVE SUSTAINABLE ACCESS TO PREDICTABLE FUNDING, QUALITY SUPPLY AND INNOVATIVE TECHNOLOGIES.**
   - Percentage of doses of vaccine used worldwide that are of assured quality
   - Progress towards development of HIV, TB, and malaria vaccines
   - Progress towards a universal influenza vaccine (protecting against drift and shift variants)
   - Progress towards institutional and technical capacity carry out vaccine clinical trials
   - Number of vaccines that have either been re-licensed or licensed for use in a controlled-temperature chain at temperatures above the traditional 2-8 °C range
   - Number of vaccine delivery technologies (devices and equipment) that have received WHO pre-qualification compared to 2010

6. **COUNTRY, REGIONAL AND GLOBAL RESEARCH AND DEVELOPMENT INNOVATIONS MAXIMIZE THE BENEFITS OF IMMUNIZATION.**
   - Progress towards development of HIV, TB, and malaria vaccines
   - Progress towards a universal influenza vaccine (protecting against drift and shift variants)
   - Progress towards institutional and technical capacity carry out vaccine clinical trials
   - Number of vaccines that have either been re-licensed or licensed for use in a controlled-temperature chain at temperatures above the traditional 2-8 °C range
   - Number of vaccine delivery technologies (devices and equipment) that have received WHO pre-qualification compared to 2010

---

2. Provisional indicator to be finalized based on outcomes of pilot assessment in selected regions
3. The report on progress will also include a narrative report on progress with vaccine supply, pricing and procurement.